Center for Addiction Medicine

News

Smoking Cessation Medications Do Not Appear to Increase Risk of Neuropsychiatric Side Effects

The Lancet

The smoking cessation medications varenicline and bupropion do not appear to increase the incidence of serious neuropsychiatric side effects compared to placebo, according to a study published in The Lancet in April, this paper provides details of the FDA-requested study that involved over 8,000 people. Read about it in the Lancet and ScienceDaily. Laurie Zawertailo comments…MORE

Smoking Cessation Benefits Persist in Spite of Weight Gain in Patients with Mental Illness

The weight gain that can result from quitting smoking does not eliminate the reduction in cardiovascular risks associated with smoking cessation among patients with serious mental illness, at least not during the first year. A report from a Massachusetts General Hospital (MGH)-based research team, published online in The Journal of Clinical Psychiatry  describes the results…MORE

Different Responses in the Brains of Young Marijuana Users

Young man smoking pot

A study by CAM researchers published in the journal Biological Psychiatry Cognitive Neuroscience and Neuroimaging finds that the brains of young adult marijuana users react differently to social exclusion than do those of non-users. Learn more in a press release from MGH and on the Science Explorer website.

Research on Pot and the Teen Brain

Research on Pot and the Teen Brain

A new CAM study targets young marijuana smokers, focusing on how drug abstinence impacts cognitive skills of teen subjects. An article in proto, MGH’s online magazine, looks at the study and others, and talks about how changing laws are creating a more accepting environment for a substance that might have more lasting effects than most…MORE

Videos of Proceedings of the Marijuana and Cannabinoids Summit Now Available

Marijuana and Cannabinoids: A Neuroscience Research Summit (March 22-23)

Dr. Evins spoke and Drs. Randi Schuster and Jodi Gilman presented their latest studies at the Neuroscience Research Summit, convened by the National Institutes of Health (NIH). The summit focused on the neurological and psychiatric effects of marijuana, other cannabinoids, and the endocannabinoid system. The goal of this summit was to ensure that evidence-based information…MORE

For individuals diagnosed with serious mental illness, quitting smoking has a net benefit

Weight gain is a prominent concern for individuals who quit smoking. While prior research has shown an overall net benefit of quitting smoking even when weight gain is considered (see here), individuals with mental illness are typically not included in this research. According to a recent study published in The Journal of Clinical Psychiatry, individuals…MORE

Center Awarded $10 Million to Help Patients with Serious Mental Illness Quit Smoking

The Center for Addiction Medicine at Massachusetts General Hospital has been awarded $10 million from the Patient-Centered Outcomes Research Institute (PCORI) to study the effectiveness of two practical approaches to improve the health of people with mental illness in the community. The project will test whether tailored education to primary care doctors alone or combined…MORE

CAM Doctors at the Neuroscience Research Summit (March 22-23)

Marijuana and Cannabinoids: A Neuroscience Research Summit (March 22-23)

Dr. Evins will be speaking and Drs. Randi Schuster and Jodi Gilman presenting their latest studies at the Neuroscience Research Summit, convened by the National Institutes of Health (NIH). The summit will focus on the neurological and psychiatric effects of marijuana, other cannabinoids, and the endocannabinoid system. Both the adverse and the potential therapeutic effects of…MORE

The Association of Recovery Schools honors recovery research award recipients

On December 5th in Washington, D.C., the national Association of Recovery Schools hosted their Annual Recovery Research Awards Banquet. RRI director John F. Kelly, Ph.D. received the Recovery Researcher of the Year Award for Outstanding Contributions to the Advancement of Advocacy and Public Policy through Science. The awards banquet was attended by several staff from federal…MORE

Can benefits of brief interventions to curb drinking in primary care be extended to the pharmacy?

What problem does this study address? Dozens of randomized controlled trials suggest that brief interventions (30 minutes or less) delivered in primary health care settings can reduce drinking by 1 to 3 drinks per week, on average, and may also reduce the incidence of risky or problematic drinking (see here). The pharmacy is another potential…MORE